ArticleBlood cancer journal2024
Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia.Cytotherapy · 2026Article
- Two birds, one BiTE: blinatumomab achieves concurrent B-ALL control and EBV clearance in post-HSCT patients: two cases report.BMC pediatrics · 2026Article
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
- Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia.Blood cancer journal · 2026Article
- [Application of blinatumomab in adult acute B-lymphoblastic leukemia: a comprehensive strategy from remission induction to post-transplantation maintenance].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia.Frontiers in immunology · 2026Article
- Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager.Oncoimmunology · 2025Article
- [Clinical application value of detecting the mutation load of the FLT3-ITD gene before allogeneic hematopoietic stem cell transplantation using PCR-NGS technology].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer.Iranian journal of basic medical sciences · 2025Review
- Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Jiayu Huang *State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.ORCID 0000-0003-1881-8313
Bingyang Shi *Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Suhui Yu *Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200136, China.ORCID 0009-0003-9811-9332
Mengxing XueNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215006, China.
Ling WangCollaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jieling JiangCollaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jiong HuCollaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.ORCID 0000-0002-5613-1195
Jun ZhuGoBroad Medical Institute of Hematology (Shanghai Center), Liquan Hospital, Shanghai, 200433, China.
Suning ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215006, China. chensuning@sina.com.
Lijing ShenDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200136, China. shenlijing@renji.com.ORCID 0000-0003-2689-1991
Weijie CaoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. caoweijie2003@126.com.ORCID 0000-0001-6977-7406
Yang CaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. caoyangemma@163.com.
Xiaoxia HuState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. hu_xiaoxia@126.com.ORCID 0000-0002-2719-3805
Funding
National Natural Science Foundation of China (National Science Foundation of China) 82170206
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, BispecificHematopoietic Stem Cell TransplantationPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAgedAntineoplastic AgentsFemaleHumansMaintenance ChemotherapyMaleMiddle AgedTransplantation, HomologousTreatment OutcomeYoung AdultAntibodies, BispecificAntineoplastic Agentsblinatumomab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.